sciencealert.com
Experimental One-Dose Treatment Cuts 'Bad' Cholesterol by 52% in First Human Trial: a precise DNA-editing approach, using CRISPR technology to make a permanent genetic change that could durably reduce LDL cholesterol after a single treatment.
Experimental One-Dose Treatment Cuts 'Bad' Cholesterol by 52% in First Human Trial: a precise DNA-editing approach, using CRISPR technology to make a permanent genetic change that could durably reduce LDL cholesterol after a single treatment.